Valiant Laboratories Limited

NSE VALIANTLAB.NS

Valiant Laboratories Limited Revenue for the year ending March 31, 2024: USD 21.83 M

Valiant Laboratories Limited Revenue is USD 21.83 M for the year ending March 31, 2024, a -46.27% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.
  • Valiant Laboratories Limited Revenue for the year ending March 31, 2023 was USD 40.63 M, a 5.82% change year over year.
  • Valiant Laboratories Limited Revenue for the year ending March 31, 2022 was USD 38.39 M, a 54.15% change year over year.
  • Valiant Laboratories Limited Revenue for the year ending March 31, 2021 was USD 24.91 M.
Key data
Date Revenue Gross Profit Operating Income EBIT
Market news
SV Wall Street
NSE: VALIANTLAB.NS

Valiant Laboratories Limited

CEO Mr. Santosh Shantilal Vora
IPO Date Oct. 6, 2023
Location India
Headquarters 104, Udyog Kshetra
Employees 77
Sector Industrials
Industries
Petrochemicals Chemicals & Advanced Materials Cleaning Supplies Drugstores & Retail Pharmacies Non-Alcoholic Beverages Personal Care Pharmaceuticals Plastics
Description

Valiant Laboratories Limited operates as an active pharmaceutical ingredient/bulk drug manufacturing company in India and internationally. The company manufactures paracetamol in various grades, such as Indian/British/European/the United States pharmacopeias for the treatment of headaches, muscle aches, arthritis, back aches, toothaches, cold, and fever. It also offers specialty chemicals. The company was formerly known as Bharat Chemicals and changed its name to Valiant Laboratories Limited in August 2021. The company was founded in 1980 and is based in Mumbai, India. Valiant Laboratories Limited is a subsidiary of Dhanvallabh Ventures LLP.

StockViz Staff

February 2, 2025

Any question? Send us an email